GLP1R and type 2 diabetes mellitus: Many individuals with type II diabetes are prescribed drugs that target the glucagon-like peptide 1 receptor (GLP-1R) due to the clinical benefit of enhancing the release of insulin while also decreasing appetite (Müller et al., 2019).